Mease PJ, Kellner H, Morita A, et al. Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis. ACR 2017, abstract 2L.
Gunstige effecten van belimumab op nieruitkomsten bij patiënten met lupus nefritis
jan 2022 | Chronische nierschade, SLE